Anna Sureda, MD, PhD, is the Head of the Clinical Hematology Service at the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain. Dr Sureda completed her medical studies at the Autonomous University of Madrid, Madrid, Spain, in 1986 followed by her residency in hematology and hemotherapy at the Ramón y Cajal Hospital, Madrid, Spain, in 1990. Shortly afterwards, Dr Sureda worked as a Hematology Consultant at the Clinical Hematology Unit of the Santa Creu i Sant Pau Hospital, Barcelona, Spain. She then moved to Cambridge, UK, where she was appointed as a Senior Consultant in Lymphomas and the Transplantation of Hematopoietic Progenitors, before heading back to Barcelona to work as Head of the Onco-Hematology Section and Hematology Service, Dexeus University Hospital, Barcelona, Spain.
Speaking on Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma
Dr Sureda’s primary research interest lies in the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma, focusing on novel therapies such as the combination of immunotherapy with allogeneic transplantation and targeted therapies. Dr Sureda’s most recent involvements include the ECHELON-1 study evaluating combination strategies for high-risk patients with Hodgkin lymphoma as well as the Phase II PANORAMA-3 study investigating oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with multiple myeloma.